Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Director N Anthony Coles Sells 50,000 Shares of Stock

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CEREGet Free Report) Director N Anthony Coles sold 50,000 shares of the company’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $42.10, for a total transaction of $2,105,000.00. Following the sale, the director now directly owns 15,638 shares in the company, valued at $658,359.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

N Anthony Coles also recently made the following trade(s):

  • On Monday, March 4th, N Anthony Coles sold 50,000 shares of Cerevel Therapeutics stock. The shares were sold at an average price of $41.01, for a total value of $2,050,500.00.
  • On Thursday, February 29th, N Anthony Coles sold 50,000 shares of Cerevel Therapeutics stock. The stock was sold at an average price of $41.16, for a total value of $2,058,000.00.

Cerevel Therapeutics Trading Up 0.4 %

CERE stock opened at $42.24 on Wednesday. Cerevel Therapeutics Holdings, Inc. has a 52-week low of $19.59 and a 52-week high of $43.59. The business has a 50-day simple moving average of $42.14 and a two-hundred day simple moving average of $38.82. The company has a current ratio of 10.22, a quick ratio of 10.22 and a debt-to-equity ratio of 0.60.

Wall Street Analysts Forecast Growth

Separately, Mizuho boosted their target price on shares of Cerevel Therapeutics from $25.00 to $45.00 and gave the company a “neutral” rating in a research report on Friday, February 16th. Eight research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $42.67.

Check Out Our Latest Stock Analysis on Cerevel Therapeutics

Hedge Funds Weigh In On Cerevel Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp raised its holdings in Cerevel Therapeutics by 1.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 263,690 shares of the biotechnology company’s stock valued at $5,756,000 after acquiring an additional 3,590 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Cerevel Therapeutics by 19.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,079 shares of the biotechnology company’s stock valued at $264,000 after purchasing an additional 1,925 shares in the last quarter. TD Asset Management Inc raised its stake in shares of Cerevel Therapeutics by 82.9% during the 3rd quarter. TD Asset Management Inc now owns 372,146 shares of the biotechnology company’s stock valued at $8,124,000 after purchasing an additional 168,697 shares during the period. Teacher Retirement System of Texas lifted its holdings in Cerevel Therapeutics by 4.8% during the 3rd quarter. Teacher Retirement System of Texas now owns 17,818 shares of the biotechnology company’s stock worth $389,000 after purchasing an additional 818 shares in the last quarter. Finally, Barclays PLC boosted its stake in Cerevel Therapeutics by 11.1% in the 3rd quarter. Barclays PLC now owns 145,910 shares of the biotechnology company’s stock worth $3,185,000 after purchasing an additional 14,568 shares during the period. 87.73% of the stock is owned by institutional investors.

About Cerevel Therapeutics

(Get Free Report)

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.

Further Reading

Insider Buying and Selling by Quarter for Cerevel Therapeutics (NASDAQ:CERE)

Receive News & Ratings for Cerevel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerevel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.